Buscar
Results for 'cardiology'
Clear-
Renown Health Welcomes New Vice President, Pharmacy
Adam D. Porath, Pharm.D., BCACP, BCPS-AQ Cardiology is promoted to serve future generations and improve the health and well-being of Nevadans. Renown Health is excited to announce Dr. Adam Porath has been promoted to vice president, pharmacy to lead clinical pharmacy and pharmacy operations and ensure excellent care for patients and families. “We are pleased to promote an experienced and talented leader like Dr. Adam Porath,” said Dawn D Ahner, DSc, FACHE, Chief Operating Officer, Acute Services. “Adam seguirá fomentando una cultura de cuidado y excelencia, y, a la vez, garantizará el más alto nivel de práctica y experiencia farmacéuticas tanto para los proveedores de atención como para los pacientes”. El Dr. Porath ha desempeñado funciones dentro del área de Farmacia en Renown desde 2006. Desde junio de 2020, ha desempeñado el cargo de director interino de Farmacia, donde dirigió la planificación estratégica de las operaciones de farmacia, dirigió a estudiantes y residentes, identificó oportunidades de crecimiento comercial, desarrolló servicios farmacéuticos clínicos novedosos y supervisó el aseguramiento de la calidad de las operaciones farmacéuticas. He began his career as a pharmacy practice resident at Renown Regional Medical Center in Reno. “I am honored to be given the opportunity to serve the medical community and patients of Renown Health,” said Dr. Porath. “What a source of pride it is to be able to deliver the high-quality, compassionate patient care Renown is known for, and to help serve and lead in the pharmacy profession.” Dr. Porath received his doctor of pharmacy degree from Idaho State University. He is a board certified pharmacotherapy specialist with added qualifications in cardiology and board certified ambulatory care pharmacist. Dr. Porath has a BS in Biology from the University of Nevada, Reno. Dr. Porath serves as adjunct clinical faculty for several colleges of pharmacy including the University of New England, Oregon State University, University of New Mexico, Idaho State University and University of Wyoming. Ha publicado sus trabajos en varias revistas revisadas por pares, como CHEST, Clinical Infectious Diseases y Canadian Medical Association Journal. Aquí en Nevada, el Dr. Porath presionó con éxito a la Legislatura de Nevada en nombre de la Nevada Society of Health System Pharmacists (NVSHP) para que se aprobara en 2011 la ley sobre la Gestión colaborativa de la terapia de medicamentos (Collaborative Drug Therapy Management, CDTM), que permite a los farmacéuticos de Nevada ajustar la terapia de medicamentos de acuerdo con un protocolo firmado por el médico en cualquier entorno de práctica, siempre que el farmacéutico esté bajo la supervisión directa de un médico. Actualmente, 48 estados permiten algún grado de CDTM. En 2017, Adam ayudó a aprobar una nueva ampliación de la ley de práctica farmacéutica. He is currently serving as a director at large of the NVSHP board. El Dr. Porath se ha desempeñado como un delegado del estado de Nevada en el Cámara de Delegados de la American Society of Health System Pharmacists (ASHP) desde 2012. En 2018, el Dr. Porath fue designado para formar parte de la asociación estatal del Fiscal General de Nevada sobre la crisis de opioides. En 2019, fue nombrado miembro del Consejo de Políticas Públicas de la ASHP. En el ranking de mejores hospitales de U.S. News and World Report, el Renown South Meadows Medical Center ocupa el primer puesto en el estado de Nevada. Renown Regional Medical Center fue nombrado en el puesto n.º 2 de los mejores hospitales en Nevada. A hospital's score is based on multiple data categories, including patient outcomes, safety and volumes. Hospitals earning a high performing rating were significantly better than the national average. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project® . Visite renown.org para obtener más información.
Leer más About Renown Health da la bienvenida al nuevo vicepresidente de Farmacia
-
Name-Brand Medication vs. Generic: What's the Difference?
Most prescriptions meds are available in generic form. Find out the similarities and differences between the two and how to determine whether a generic is right for you. Approximately 80 percent of prescriptions sold today are generics. If you’re taking a prescription medication, chances are it’s a generic form of the brand-name drug. But are you getting the same quality in a generic medication? Do generics measure up? The answer in most cases is yes — generics, just like branded products, are regulated by the Food and Drug Administration. “To have a generic product approved by the FDA, the generic manufacturer must prove that its product is bioequivalent to the branded product,” explains Adam Porath, PharmD, BCPS AQ-Cardiology, BCACP and Vice President of Pharmacy Services. Basically, it has to function the same. “Generic products are extremely well tolerated and will provide the same results as using a branded product,” Porath says. Here’s how generics are the same as name-brand prescriptions: Generic products contain the same active ingredients. They produce the same desired clinical effect and accompanying side effects. Generics come in the same form as their branded counterparts: pill, liquid or inhaler, for example. Release into the bloodstream matches the name brand in timing and strength. Here’s how they differ: Generics generally cost less. Federal law requires generics have different names and look different: shape, size, markings and color. Generics contain different inactive ingredients, like binders, fillers and artificial colors. Different side effects with generics can usually be attributed to these additions. Why do generics cost less? When pharmaceutical companies develop a new drug, they are paying for research, development, clinical studies, marketing — in some cases it can cost more than $800 million and take 10 to 15 years to develop a new drug. “The manufacturers of branded medication products have to recoup their research and development costs,” Porath says. So companies are granted a limited patent to sell their drug without the competition of generic counterparts. “When patent exclusivity ends, the market is open for any generic manufacturer to make a competing product with FDA approval.” Without the same startup costs, companies can sell generics at 80 to 85 percent less. And because more than one company can produce the same generics, competition drives prices even lower.
Read More About Name-Brand Medication vs. Generic: What's the Difference?